Subsense, a Palo Alto-based neurotechnology company developing non-surgical, nanoparticle-based brain-computer interfaces, has expanded its financing to $27 million following the close of a new $10 million investment. The additional capital builds on earlier funding and is intended to accelerate research and development efforts as the company advances its platform toward product development and clinical translation.
Golden Falcon Capital led the latest investment and follows Subsense’s description of early breakthroughs in materials development, in vitro nanoparticle stimulation, and neural signal reading. With the new funding, the company plans to intensify work across several core areas, including nanoparticle sensing, in vivo biosafety programs, next-generation nanoparticle design, and the continued miniaturization of its proprietary hardware.
Founded to address the limitations of surgically implanted brain-computer interfaces, Subsense is developing a bidirectional neural interface platform designed to record and modulate brain activity without the need for implanted electrodes or invasive procedures.
The company’s approach combines engineered nanoparticles, which are administered nasally and designed to cross the blood-brain barrier, with custom-built hardware and signal-processing software. Together, these components are intended to deliver high-resolution neural reading and stimulation while reducing the risks, costs, and accessibility barriers associated with traditional invasive systems.
Subsense’s technology platform spans multiple disciplines, including nanoparticle chemistry, magnetic signal transduction, and proprietary neural decoding algorithms. The company says its system is designed to be safe, reversible, and adaptable, allowing for future updates and reconfigurations as nanoparticle formulations and signal models evolve. Unlike fixed implanted hardware, the platform is intended to remain compatible with ongoing advances in neurotechnology without requiring surgical replacement.
As part of its expansion, Subsense has recently opened a new laboratory and engineering facility in Palo Alto, California. The company also maintains research collaborations with neurological research institutions across North America and Europe, supporting its efforts to validate and scale its technology.
The financing comes amid growing global interest in non-surgical and hybrid brain-computer interface approaches, as researchers and companies seek to overcome the accessibility and biosafety challenges that have limited the widespread adoption of invasive neural systems. Industry forecasts cited by the company suggest the global brain-computer interface market could exceed $3 billion by 2030, driven by advances in materials science, machine learning, and the convergence of health and computing technologies.
Subsense is venture-backed and positions its nanoparticle-based model as a potential pathway to population-scale neural data capture without surgery, anesthesia, or permanently implanted devices, aiming to broaden the reach of brain-computer interfaces beyond specialized clinical settings.
KEY QUOTES:
“We are developing a new kind of neural interface, which integrates seamlessly with the human body. This bio-integrated approach is fundamentally enhancing safety and expanding accessibility.”
Tetiana Aleksandrova, Co-Founder And Chief Executive Officer, Subsense
